Source comparison
Comparative Trials: Modified Versus Unmodified CJC-1295 Outcomes
The terminology confusion around CJC-1295 stems from two chemically distinct peptides sharing nearly identical names. CJC-1295 with DAC (also called CJC-1295 DAC) refers to the albumin-binding variant with extended half-life. CJC-1295 without DAC. More accurat
This comparison does not assign a generated winner or score.
- The terminology confusion around CJC-1295 stems from two chemically distinct peptides sharing nearly identical names. CJC-1295 with DAC (also called CJC-1295 DAC) refers to the albumin-binding variant with extended half-life. CJC-1295 without DAC. More accurately called Modified GRF (1-29) or Mod GRF. Lacks the lysine-MPA-DAC modification and behaves pharmacokinetically like tesamorelin or sermorelin, with a plasma half-life under 30 minutes.
- A 2014 head-to-head comparison published in Growth Hormone & IGF Research tested both variants in a crossover design. Participants received either 100 mcg of Modified GRF (1-29) three times daily or 60 mcg/kg of CJC-1295 with DAC once weekly for eight weeks, with a four-week washout between phases. The Modified GRF group showed preserved pulsatile GH secretion: nocturnal GH pulse amplitude increased by 60–80% without elevating daytime trough GH. The CJC-1295 DAC group showed tonic elevation: mean 24-hour GH concentration increased by 140%, but pulse amplitude decreased by 35%. IGF-1 levels rose comparably in both groups (55–65% above baseline), but the Modified GRF group returned to baseline within 48 hours of stopping, whereas the CJC-1295 DAC group remained elevated for 12–14 days post-final injection.
- The clinical takeaway: if preserving physiological GH pulsatility matters. Whether for maintaining natural feedback regulation, minimizing desensitization risk, or mimicking endogenous patterns. Modified GRF (1-29) is the appropriate choice despite requiring multiple daily injections. If sustained IGF-1 elevation and dosing convenience are priorities, CJC-1295 with DAC delivers but at the cost of overriding natural pulsatility.
- A 2018 meta-analysis in Peptides reviewed 14 controlled trials of GHRH analogues (including CJC-1295, tesamorelin, and sermorelin) and found that albumin-binding modifications consistently produced 2.5–3.5× longer duration of IGF-1 elevation compared to non-binding analogues, but also showed 40–50% higher rates of peripheral edema and carpal tunnel symptoms. Adverse effects associated with sustained supraphysiological IGF-1 rather than pulsatile GH itself.